MXPA02011553A - Bicyclyl or heterobicyclylmethanesulfonylamino substituted n hydroxyformamides. - Google Patents

Bicyclyl or heterobicyclylmethanesulfonylamino substituted n hydroxyformamides.

Info

Publication number
MXPA02011553A
MXPA02011553A MXPA02011553A MXPA02011553A MXPA02011553A MX PA02011553 A MXPA02011553 A MX PA02011553A MX PA02011553 A MXPA02011553 A MX PA02011553A MX PA02011553 A MXPA02011553 A MX PA02011553A MX PA02011553 A MXPA02011553 A MX PA02011553A
Authority
MX
Mexico
Prior art keywords
bicyclyl
hydroxyformamides
heterobicyclylmethanesulfonylamino
substituted
heterobicyclyl
Prior art date
Application number
MXPA02011553A
Other languages
Spanish (es)
Inventor
Desmond John Best
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0012809A external-priority patent/GB0012809D0/en
Priority claimed from GB0104970A external-priority patent/GB0104970D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MXPA02011553A publication Critical patent/MXPA02011553A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)

Abstract

Compounds of formula (I): R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R1 is bicyclyl or heterobicyclyl, are useful in the treatment and prophylaxis of conditions mediated by s CD23.
MXPA02011553A 2000-05-25 2001-05-21 Bicyclyl or heterobicyclylmethanesulfonylamino substituted n hydroxyformamides. MXPA02011553A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0012809A GB0012809D0 (en) 2000-05-25 2000-05-25 Novel compounds
GB0104970A GB0104970D0 (en) 2001-02-28 2001-02-28 Novel compounds
PCT/EP2001/005798 WO2001090100A1 (en) 2000-05-25 2001-05-21 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides

Publications (1)

Publication Number Publication Date
MXPA02011553A true MXPA02011553A (en) 2003-04-25

Family

ID=26244357

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011553A MXPA02011553A (en) 2000-05-25 2001-05-21 Bicyclyl or heterobicyclylmethanesulfonylamino substituted n hydroxyformamides.

Country Status (20)

Country Link
US (2) US20040024066A1 (en)
EP (1) EP1289980B1 (en)
JP (1) JP2004501108A (en)
KR (1) KR20030005392A (en)
CN (1) CN1440400A (en)
AR (1) AR032341A1 (en)
AT (1) ATE282603T1 (en)
AU (1) AU2001267468A1 (en)
BR (1) BR0111074A (en)
CA (1) CA2410294A1 (en)
CZ (1) CZ20023853A3 (en)
DE (1) DE60107240T2 (en)
ES (1) ES2231513T3 (en)
HU (1) HUP0302121A2 (en)
IL (1) IL152990A0 (en)
MX (1) MXPA02011553A (en)
NO (1) NO20025549L (en)
NZ (1) NZ522594A (en)
PL (1) PL360116A1 (en)
WO (1) WO2001090100A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128376D0 (en) * 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel compounds
GB0302431D0 (en) * 2003-01-30 2003-03-05 Glaxo Group Ltd Novel compounds
US7271195B2 (en) 2003-06-10 2007-09-18 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
WO2004110418A2 (en) * 2003-06-10 2004-12-23 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
KR100640876B1 (en) 2004-11-17 2006-11-02 엘지전자 주식회사 Video decoding system in mobile broadcasting receiver

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
WO1999006361A2 (en) * 1997-07-31 1999-02-11 Abbott Laboratories N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
EP1051395B1 (en) * 1998-01-30 2006-11-22 Darwin Discovery Limited N-hydroxyformamide derivatives
AU751780B2 (en) * 1998-02-06 2002-08-29 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds

Also Published As

Publication number Publication date
WO2001090100A1 (en) 2001-11-29
JP2004501108A (en) 2004-01-15
EP1289980A1 (en) 2003-03-12
US20050288376A1 (en) 2005-12-29
CN1440400A (en) 2003-09-03
NZ522594A (en) 2004-05-28
NO20025549D0 (en) 2002-11-19
EP1289980B1 (en) 2004-11-17
CZ20023853A3 (en) 2003-05-14
BR0111074A (en) 2003-06-24
DE60107240D1 (en) 2004-12-23
HUP0302121A2 (en) 2003-10-28
AR032341A1 (en) 2003-11-05
CA2410294A1 (en) 2001-11-29
ES2231513T3 (en) 2005-05-16
NO20025549L (en) 2003-01-24
AU2001267468A1 (en) 2001-12-03
US20040024066A1 (en) 2004-02-05
PL360116A1 (en) 2004-09-06
KR20030005392A (en) 2003-01-17
IL152990A0 (en) 2003-06-24
ATE282603T1 (en) 2004-12-15
DE60107240T2 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
BE2017C018I2 (en)
BR0114045A (en) Polyarylcarboxamides useful as lipid lowering agents
AU8473301A (en) Non-imidazole aryloxyalkylamines
DE60330150D1 (en) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
MY135841A (en) Novel benzodioxoles
NO20054404L (en) 5,7-Diaminopyrazolo [4,3-D] Pyrimidines Useful in the Treatment of Hypertension
HK1033463A1 (en) 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
DE60112974D1 (en) Carbolinderivate
AU2002316459A1 (en) Methods of treating cytokine mediated diseases
GB0209891D0 (en) Novel compounds
GB0127903D0 (en) Improvements relating to organic compounds
NZ510369A (en) Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
DE60216233D1 (en) Carbolinderivate
MXPA03002911A (en) Chemical compounds.
MXPA02012659A (en) Chemical compounds.
NO20043016L (en) 6-aminomorphinan derivatives, process for preparation and use thereof
ATE303384T1 (en) 1-BIARYL-1,8-NAPHTHYRIDINE-4-ONE AS PHOSPHODIESETERASE INHIBITORS
IL158324A0 (en) Arylsulphonamides as anttiviral agents
MXPA04006041A (en) Pyridoquinoxaline antivirals.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
MXPA02011553A (en) Bicyclyl or heterobicyclylmethanesulfonylamino substituted n hydroxyformamides.
DE602004018811D1 (en) PYRROLIDINE HYDROGEN DERIVATIVES AS ANGIOGENESE INHIBITORS
DE60041001D1 (en) SUBSTITUTED HOMOPIPERIDYLBENZIMIDAZOLANALOGA AS FUNDUSRELAXANTIA
DE60121048D1 (en) PYRAZINOi1'2 ': 1,6öPYRIDOi3,4-BöINDOLDERIVATE
MXPA04005151A (en) Therapeutic compounds.